NCT05334329 is a first-in-human phase 1 dose-finding study of allogeneic, off-the-shelf, frozen and thawed, tumor-reactive anti-PD-L1 co-stimulated killer cells (TRACK-NK) in patients with PD-1-resistant NSCLC [59]. Here, CD274 is linked to neoplasm.